The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
ApexOnco Front Page
Recent articles
After menin, the company tries again with farnesyl transferase.
Failed trials of vibostolimab and domvanalimab will be unveiled at SITC late-breakers.
After beating "historical" Xtandi masofaniten fails to beat actual Xtandi.
October's US approvals included Scemblix, Vyloy and Itovebi, while Lumakras was delayed.
Conferences ramp up, and ASH abstracts near.
The group goes after a KRAS-related target on which Boehringer recently gave up.
Pelabresib is delayed, and Novartis writes off $800m of the €2.7bn purchase.
